iCAD, Inc. (ICAD)

Market Cap	32.57M
Revenue (ttm)	29.26M
Net Income (ttm)	-14.71M
Shares Out	25.45M
EPS (ttm)	-0.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	144,866
Open	1.28
Previous Close	1.26
Day's Range	1.27 - 1.32
52-Week Range	1.16 - 4.68
Beta	1.21
Analysts	Buy
Price Target	5.30 (+314.06%)
Earnings Date	Mar 28, 2023

About ICAD

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calci...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Dec 3, 1986
• Employees: 136
• Stock Exchange: NASDAQ
• Ticker Symbol: ICAD

Financial Performance

In 2021, iCAD, Inc.'s revenue was $33.64 million, an increase of 13.27% compared to the previous year's $29.70 million. Losses were -$11.25 million, -36.14% less than in 2020.

Analyst Forecast

According to 12 analysts, the average rating for ICAD stock is "Buy." The 12-month stock price forecast is $5.3, which is an increase of 314.06% from the latest price.

Price Target

$5.3

(314.06% upside)

Analyst Consensus: Buy